Pro-Dex Q4 EPS Lifted by Ascendiant Capital Markets

Key Points

• Ascendiant Capital Markets raised Pro-Dex’s Q4 2027 EPS estimate to $0.87 from $0.70 and maintained a Buy rating with a $74 price target.
• Pro-Dex’s latest quarter exceeded expectations, reporting $0.87 EPS versus the $0.67 consensus and revenue of $20.4 million versus $19.2 million expected.
• Analyst sentiment remains positive, with the stock carrying a consensus Buy rating and a $74 average target price; however, insiders sold shares worth about $1.35 million over the past three months.

Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) - Equities research analysts at Ascendiant Capital Markets increased their Q4 2027 earnings per share estimates for shares of Pro-Dex in a report released on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now anticipates that the medical instruments supplier will earn $0.87 per share for the quarter, up from their prior estimate of $0.70. Ascendiant Capital Markets has a "Buy" rating and a $74.00 price target on the stock. The consensus estimate for Pro-Dex's current full-year earnings is $3.09 per share.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings data on Thursday, September 3rd. The medical instruments supplier reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.20. The firm had revenue of $20.40 million during the quarter, compared to analysts' expectations of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%.

PDEX has been the topic of a number of other reports. Zacks Research upgraded Pro-Dex from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Weiss Ratings upgraded shares of Pro-Dex from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, September 4th. Finally, Wall Street Zen upgraded shares of Pro-Dex from a "hold" rating to a "buy" rating in a report on Saturday, June 13th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, Pro-Dex presently has a consensus rating of "Buy" and an average target price of $74.00.

Pro-Dex Price Performance

Shares of NASDAQ:PDEX opened at $71.85 on Thursday. The company has a quick ratio of 2.45, a current ratio of 4.10 and a debt-to-equity ratio of 0.28. Pro-Dex has a twelve month low of $23.47 and a twelve month high of $77.00. The stock's 50 day moving average is $62.92 and its 200-day moving average is $58.37. The firm has a market capitalization of $229.92 million, a price-to-earnings ratio of 17.40 and a beta of 0.06.

Hedge Funds Weigh In On Pro-Dex

Large investors have recently bought and sold shares of the stock. Navellier & Associates Inc. bought a new stake in shares of Pro-Dex in the 2nd quarter worth $322,000. Bank of New York Mellon Corp bought a new position in shares of Pro-Dex during the second quarter valued at about $678,000. Corsair Capital Management L.P. bought a new position in shares of Pro-Dex during the first quarter valued at about $532,000. Punch & Associates Investment Management Inc. boosted its holdings in Pro-Dex by 2.9% during the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier's stock worth $3,032,000 after purchasing an additional 1,735 shares during the last quarter. Finally, Morgan Dempsey Capital Management LLC boosted its holdings in Pro-Dex by 6.2% during the first quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier's stock worth $286,000 after purchasing an additional 339 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Alisha Charlton sold 2,300 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total value of $140,990.00. Following the completion of the sale, the chief financial officer directly owned 21,870 shares of the company's stock, valued at $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total value of $45,410.40. Following the completion of the transaction, the chief executive officer owned 79,228 shares in the company, valued at $4,702,974.08. This represents a 0.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,300 shares of company stock valued at $1,351,657 over the last three months. Corporate insiders own 45.90% of the company's stock.

Pro-Dex News Summary

Here are the key news stories impacting Pro-Dex this week:

• Positive Sentiment: Ascendiant raised its FY2027 EPS forecast to $3.09 from $2.78, while increasing estimates for Q1, Q2, and Q3 2027. The firm also lifted its Q4 2027 forecast to $0.87 from $0.70, signaling expectations for stronger profitability at the medical-instruments supplier.
• Positive Sentiment: Ascendiant maintained a Buy rating and a $74 price target. Its longer-term projections call for FY2028 EPS of $3.36, with quarterly estimates ranging from $0.77 to $0.91.
• Positive Sentiment: The revised FY2027 outlook is above the previously cited $2.78 consensus estimate, which may reinforce the view that Pro-Dex’s earnings momentum is improving.

Pro-Dex Company Profile

Pro-Dex, Inc is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands.

Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers.

Based in Irvine, California, Pro-Dex serves customers in the United States and international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.